Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Reverse transcription and quantitative PCR Cells were seeded in six-well dishes and treated with desired reagents
24 April 2018
What The FDA Category 1 vs Category 2 Status Means Today Under the FDAs interim bulk substances framework for 503A compounding pharmacies: Category 1: Bulk Drug Substances under evaluation with sufficient supporting safety information
R Clinical implications of slow acetylation: Increased risk of isoniazid-induced hepatotoxicity and peripheral neuropathy (tuberculosis treatment) R Increased risk of sulfonamide hypersensitivity reactions R Increased risk of aromatic amine-related bladder cancer in occupational exposure settings (dye workers, rubber industry) R Drug-induced lupus from hydralazine and procainamide occurs almost exclusively in slow acetylators R Altered caffeine metabolism (slow acetylators clear caffeine more slowly via the NAT2 pathway) R NAT1 polymorphisms are less well characterized but the slow allele NAT1*14 has been associated with increased risk of cancers from dietary aromatic amines
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
